MIM
OVID icon

MetLife Investment Management’s Ovid Therapeutics OVID Stock Holding History

MetLife Investment Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,796
Closed -$46.7K – 2912
2024
Q1 		$51.2K Sell
16,796
-14,921
-47% -$49.9K ﹤0.01% 2713
2023
Q4 		$102K Hold
31,717
– – ﹤0.01% 2598
2023
Q3 		$122K Hold
31,717
– – ﹤0.01% 2478
2023
Q2 		$104K Buy
+31,717
New +$108K ﹤0.01% 2655
2020
Q4 		– Sell
-20,939
Closed -$120K – 2299
2020
Q3 		$120K Hold
20,939
– – ﹤0.01% 2129
2020
Q2 		$154K Buy
+20,939
New +$97.9K ﹤0.01% 2047

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MetLife Investment Management's OVID Position: Q2 2024 in Review

MetLife Investment Management sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 16,796 shares — an estimated $46.7K sold.

MetLife Investment Management first reported a position in OVID in Q2 2020 and held it in 6 quarters. The position peaked at $154K in Q2 2020. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • MetLife Investment Management reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • MetLife Investment Management sold 16,796 Ovid Therapeutics shares in Q2 2024, an estimated $46.7K.
  • MetLife Investment Management first reported a position in Ovid Therapeutics in Q2 2020 and held it in 6 quarters.
  • MetLife Investment Management's Ovid Therapeutics position peaked at $154K in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.